Condition
Staphylococcus Aureus Bloodstream Infection
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 4 (2)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06650501Phase 4Recruiting
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
NCT06650488Phase 4Recruiting
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
NCT06014736Phase 1UnknownPrimary
A Phase I Study of XJ101 in Chinese Healthy Subjects
Showing all 3 trials